Cetin, B. Et Al. 2013. Bevacizumab-containing Chemotherapy is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumor. JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.43, no.1 , 28-32.

Cetin, B., Kaplan, M. A., Berk, V., Tufan, G., Benekli, M., Isikdogan, A., ... ÖZKAN, M.(2013). Bevacizumab-containing Chemotherapy is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumor. JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.43, no.1, 28-32.

Cetin, Bulent Et Al. "Bevacizumab-containing Chemotherapy is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumor," JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.43, no.1, 28-32, 2013

Cetin, Bulent Et Al. "Bevacizumab-containing Chemotherapy is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumor." JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.43, no.1, pp.28-32, 2013

Cetin, B. Et Al. (2013) . "Bevacizumab-containing Chemotherapy is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumor." JAPANESE JOURNAL OF CLINICAL ONCOLOGY , vol.43, no.1, pp.28-32.

@article{article, author={Bulent Cetin Et Al. }, title={Bevacizumab-containing Chemotherapy is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumor}, journal={JAPANESE JOURNAL OF CLINICAL ONCOLOGY}, year=2013, pages={28-32} }